In Brief: Matritech
This article was originally published in The Gray Sheet
Matritech: Firm identifies three cervical cancer-specific nuclear matrix proteins (NMPs) for use as cancer markers on an automated cervical cancer screening analyzer under development at Bayer Diagnostics. The discovery "triggers a milestone payment from Bayer" under a product development and marketing option agreement reached in June 1995 ("The Gray Sheet" June 19, 1995, p. 32)...
You may also be interested in...
The UK has approved the mRNA-based vaccine just nine days after receiving the final Phase III results from Pfizer.
As the MHRA prepares to grant approval to the Oxford/AstraZeneca vaccine, Wockhardt is set to supply 100 million doses for the UK government’s own use and its WHO commitments. The company is also in talks with global vaccine developers to manufacture their COVID-19 vaccines for emerging economies
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.